Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres

被引：1
|
作者：
McCaughan, Georgia J. [1 ,2 ]
Verma, Anvita [2 ,3 ]
Ling, Silvia [2 ,3 ]
Lavee, Orly [1 ]
Moore, John J. [1 ,3 ]
Bryant, Adam [2 ,3 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Sydney, NSW, Australia
[2] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[3] Liverpool Hosp, Dept Haematol, Sydney, NSW, Australia
来源：
BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / 03期
关键词：
INDUCTION THERAPY; DEXAMETHASONE VCD; SUPERIOR; VTD;
D O I：
10.1038/s41409-020-01086-9
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：738 / 740
页数：3
相关论文
共 50 条
  • [41] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [42] MAINTENANCE THERAPY WITH BORTEZOMIB/DEXAMETHASONE IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS CARRYING HIGH RISK FEATURES
    Mancuso, K.
    Tacchetti, P.
    Pantani, L.
    Rocchi, S.
    Rizzello, I.
    Caratozzolo, I.
    De Cicco, G.
    Fusco, A.
    Testoni, N.
    Terragna, C.
    Marzocchi, G.
    Martello, M.
    Borsi, E.
    Dozza, L.
    Zamagni, E.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 50 - 50
  • [43] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [44] Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study
    Rizzello, Ilaria
    Cavo, Michele
    Dozza, Luca
    Rivolti, Elena
    Petrucci, Maria Teresa
    De Stefano, Valerio
    Antonioli, Elisabetta
    Tosi, Patrizia
    D'Agostino, Mattia
    More, Sonia
    Gozzetti, Alessandro
    Cea, Michele
    Barbato, Simona
    Tacchetti, Paola
    Pantani, Lucia
    Mancuso, Katia
    Rocchi, Serena
    De Cicco, Gabriella
    Fusco, Alessio
    Zamagni, Elena
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 1896 - 1906
  • [45] Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
    Guerrero, Camila
    Puig, Noemi
    Cedena, Maria-Teresa
    Calasanz, Maria-Jose
    Gutierrez, Norma C.
    Fernandez, Manuela
    Oriol, Albert
    Rios-Tamayo, Rafael
    Hernandez, Miguel-Teodoro
    Martinez-Martinez, Rafael
    Bargay, Joan
    de Arriba, Felipe
    Palomera, Luis
    Gonzalez-Rodriguez, Ana Pilar
    Perez, Marta -Sonia Gonzalez
    Orfao, Alberto
    Mateos, Maria -Victoria
    Martinez-Lopez, Joaquin
    Rosinol, Laura
    Blade, Joan
    Lahuerta, Juan -Jose
    San-Miguel, Jesus F.
    Paiva, Bruno
    BLOOD, 2024, 143 (07) : 597 - 603
  • [46] Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic
    Popkova, Tereza
    Pour, Ludek
    Spicka, Ivan
    Radocha, Jakub
    Jungova, Alexandra
    Minarik, Jiri
    Jelinek, Tomas
    Pavlicek, Petr
    Krejci, Marta
    Straub, Jan
    Maisnar, Vladimir
    Dekojova, Tereza
    Pika, Tomas
    Soukup, Jan
    Capkova, Lenka
    Hajek, Roman
    BLOOD, 2021, 138
  • [47] Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
    Garces, Juan-Jose
    Cedena, Maria-Teresa
    Puig, Noemi
    Burgos, Leire
    Perez, Jose J.
    Cordon, Lourdes
    Flores-Montero, Juan
    Sanoja-Flores, Luzalba
    Calasanz, Maria-Jose
    Ortiol, Albert
    Blanchard, Maria-Jesus
    Rios, Rafael
    Martin, Jesus
    Martinez-Martinez, Rafael
    Bargay, Joan
    Sureda, Anna
    de la Rubia, Javier
    Hernandez, Miguel-Teodoro
    Rodriguez-Otero, Paula
    de la Cruz, Javier
    Orfao, Alberto
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Lahuerta, Juan-Jose
    Rosinol, Laura
    Blade, Joan
    San-Miguel, Jesus F.
    Paiva, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3151 - +
  • [48] Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
    Qerimi, Vjollca
    Nestorovska, Aleksandra Kapedanovska
    Sterjev, Zoran
    Genadieva-Stavric, Sonja
    Suturkova, Ljubica
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 327 - 338
  • [49] How First-Line Therapy is Changing in Transplant-Eligible Multiple Myeloma Patients
    Houbaida, Yasmine
    Del Giudice, Maria Livia
    Galimberti, Sara
    Buda, Gabriele
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2025, 17 (01)
  • [50] Clinical outcomes of transplant-eligible multiple myeloma patients treated with frontline thalidomide/dexamethasone
    Ha, H.
    Youk, J.
    Park, H.
    Lee, J. -O
    Bang, S. -M.
    Kim, K-H.
    Park, J. -H.
    Koh, Y.
    Kim, I.
    Yoon, S. -S.
    Park, S.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5626 - 5627
12345